Court dismisses Verus suit against AZ

AstraZeneca has won dismissal of a lawsuit in which it was accused of backing out of a deal with Verus Pharmaceuticals to develop a children's asthma drug and instead aligning with competitor Map Pharmaceuticals. Verus had been seeking at least $280 million in compensatory damages and $1 billion in punitive damages. Verus claimed that once AstraZeneca entered a deal with Map, it sought to kill any competition by destroying Verus's ability to develop the drug on its own. Article | Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.